Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel monoclonal antibody therapeutics aimed at treating chronic inflammatory and immune-mediated diseases, with a primary focus on psoriasis and psoriatic arthritis. Their lead candidates, ORKA-001 and ORKA-002, target specific interleukins (IL-23p19 and IL-17A/F respectively), which are key cytokines involved in the pathogenesis of these conditions. The company applies advanced antibody engineering to optimize drug profiles with the goal of achieving higher rates of disease clearance, longer-lasting remission, and more convenient dosing schedules, potentially as infrequent as two to three times per year. Headquartered in Menlo Park, California, Oruka Therapeutics is noteworthy for advancing biologics designed to redefine standards of care in dermatology and immunology by offering improved treatments for chronic skin diseases, thus playing a distinctive role in the biopharmaceutical sector focused on immunological conditions.